Clinical data
Trade names Cardene
AHFS/ Monograph
MedlinePlus a695032
Routes of
Oral, intravenous
ATC code C08CA04 (WHO)
Legal status
Legal status
  • ℞ (Prescription only)
Pharmacokinetic data
Protein binding >95%
Biological half-life 8.6 hours
CAS Number 55985-32-5 YesY
PubChem (CID) 4474
DrugBank DB00622 YesY
ChemSpider 4319 YesY
UNII CZ5312222S YesY
KEGG D08270 YesY
ECHA InfoCard 100.054.466
Chemical and physical data
Formula C26H29N3O6
Molar mass 479.525 g/mol
3D model (Jmol) Interactive image
Melting point 136–138 °C (277–280 °F)

Nicardipine hydrochloride (Cardene) is a medication used to treat high blood pressure and angina. It belongs to the dihydropyridine class of calcium channel blockers.

Nicardipine is a dihydropyridine calcium-channel blocking agent used for the treatment of vascular disorders such as chronic stable angina, hypertension, and Raynaud's phenomenon. It is available in oral and intravenous formulations. Its mechanism of action and clinical effects closely resemble those of nifedipine and the other dihydropyridines (amlodipine, felodipine), except that nicardipine is more selective for cerebral and coronary blood vessels. Furthermore, nicardipine does not intrinsically decrease myocardial contractility and may be useful in the management of congestive heart failure. Nicardipine also has a longer half-life than nifedipine. Nicardipine was approved by the FDA in December 1988. The patent for both Cardene and Cardene SR expired in October 1995.[1]

It has been used in percutaneous coronary intervention.[2]


  1. Nicardipine at Medline PLus
  2. Huang RI, Patel P, Walinsky P, et al. (November 2006). "Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention". Catheter Cardiovasc Interv. 68 (5): 671–6. doi:10.1002/ccd.20885. PMID 17034064.

This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.